Benzamides and related inhibitors of factor XA
Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
1. A method for preventing or treating venous thrombosis in a human patient in need thereof comprising administering to said patient a tablet comprising a maleate salt of the following compound:
2. A method for preventing or treating venous thrombosis in a human patient in need thereof comprising administering to said patient a capsule comprising a maleate salt of the following compound:
3. A method for preventing or treating deep venous thrombosis in a human patient in need thereof comprising administering to said patient a tablet comprising a maleate salt of the following compound:
4. A method for preventing or treating deep venous thrombosis in a human patient in need thereof comprising administering to said patient a capsule comprising a maleate salt of the following compound:
5. A method for preventing or treating pulmonary embolism in a human patient in need thereof comprising administering to said patient a tablet comprising a maleate salt of the following compound:
6. A method for preventing or treating pulmonary embolism in a human patient in need thereof comprising administering to said patient a capsule comprising a maleate salt of the following compound:
7. The method of claim 1 , wherein the method comprises administering the tablet once daily.
8. The method of claim 2 , wherein the method comprises administering the capsule once daily.
9. The method of claim 1 , wherein the tablet further comprises microcrystalline cellulose and magnesium stearate.
10. The method of claim 2 , wherein the capsule further comprises microcrystalline cellulose and magnesium stearate.
11. The method of claim 3 , wherein the method comprises administering the tablet once daily.
12. The method of claim 5 , wherein the method comprises administering the tablet once daily.
13. The method of claim 4 , wherein the method comprises administering the capsule once daily.
14. The method of claim 6 , wherein the method comprises administering the capsule once daily.
15. The method of claim 3 , wherein the tablet further comprises microcrystalline cellulose and magnesium stearate.
16. The method of claim 5 , wherein the tablet further comprises microcrystalline cellulose and magnesium stearate.
17. The method of claim 4 , wherein the capsule further comprises microcrystalline cellulose and magnesium stearate.
18. The method of claim 6 , wherein the capsule further comprises microcrystalline cellulose and magnesium stearate.